Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy LAVA Therapeutics stock

Learn how to easily invest in LAVA Therapeutics stock.

LAVA Therapeutics NV is a biotechnology business based in the US. LAVA Therapeutics shares (LVTX) are listed on the NASDAQ and all prices are listed in US Dollars. LAVA Therapeutics employs 55 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in LAVA Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LVTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

LAVA Therapeutics stock price (NASDAQ: LVTX)

Use our graph to track the performance of LVTX stocks over time.

LAVA Therapeutics shares at a glance

Information last updated 2022-07-02.
Latest market close$3.16
52-week range$2.28 - $11.13
50-day moving average $3.28
200-day moving average $5.10
Wall St. target price$22.41
PE ratio 0.3223
Dividend yield $0 (0%)
Earnings per share (TTM) $9.79

Buy LAVA Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy LAVA Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

LAVA Therapeutics price performance over time

Historical closes compared with the close of $3.155 from 2022-07-01

1 week (2022-06-28) 8.79%
1 month (2022-06-03) 2.10%
3 months (2022-04-05) -27.47%
6 months (2022-01-05) -45.42%
1 year (2021-07-02) -70.92%
2 years (2020-07-01) N/A
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Is LAVA Therapeutics stock undervalued or overvalued?

Valuing LAVA Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LAVA Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

LAVA Therapeutics's P/E ratio

LAVA Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, LAVA Therapeutics shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, LAVA Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    LAVA Therapeutics financials

    Revenue TTM $5 million
    Gross profit TTM $-32,193,000
    Return on assets TTM -15.38%
    Return on equity TTM -29.94%
    Profit margin 0%
    Book value $4.21
    Market capitalisation $81.3 million

    TTM: trailing 12 months

    LAVA Therapeutics share dividends

    We're not expecting LAVA Therapeutics to pay a dividend over the next 12 months.

    LAVA Therapeutics overview

    LAVA Therapeutics N. V. , a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.

    Frequently asked questions

    What percentage of LAVA Therapeutics is owned by insiders or institutions?
    Currently 29.27% of LAVA Therapeutics shares are held by insiders and 55.768% by institutions.
    How many people work for LAVA Therapeutics?
    Latest data suggests 55 work at LAVA Therapeutics.
    When does the fiscal year end for LAVA Therapeutics?
    LAVA Therapeutics's fiscal year ends in December.
    Where is LAVA Therapeutics based?
    LAVA Therapeutics's address is: Yalelaan 60, Utrecht, Netherlands, 3584 CM
    What is LAVA Therapeutics's ISIN number?
    LAVA Therapeutics's international securities identification number is: NL0015000AG6

    More guides on Finder

    Ask an Expert

    You are about to post a question on finder.com:

    • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
    • finder.com is a financial comparison and information service, not a bank or product provider
    • We cannot provide you with personal advice or recommendations
    • Your answer might already be waiting – check previous questions below to see if yours has already been asked

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site